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Summary. In clinical studies, multiple superiority/equivalence testing procedures can be applied to classify
a new treatment as superior, equivalent (same therapeutic eﬀect), or inferior to each set of standard treat-
ments. Previous stepwise approaches (Dunnett and Tamhane, 1997, Statistics in Medicine 16, 2489–2506;
Kwong, 2001, Journal of Statistical Planning and Inference 97, 359–366) are only appropriate for balanced
designs. Unfortunately, the construction of similar tests for unbalanced designs is far more complex, with
two major diﬃculties: (i) the ordering of test statistics for superiority may not be the same as the ordering of
test statistics for equivalence; and (ii) the correlation structure of the test statistics is not equi-correlated but
product-correlated. In this article, we seek to develop a two-stage testing procedure for unbalanced designs,
which are very popular in clinical experiments. This procedure is a combination of step-up and single-step
testing procedures, while the familywise error rate is proved to be controlled at a designated level. Further-
more, a simulation study is conducted to compare the average powers of the proposed procedure to those
of the single-step procedure. In addition, a clinical example is provided to illustrate the application of the
new procedure.
Key words: Coherence property; Equivalent eﬃcacy; Familywise error rate; Multivariate t-distribution.
1. Introduction
The simultaneous testing of the superiority and equivalence
of the eﬃcacy between a treatment and a standard treatment
was studied by Morikawa and Yoshida (1995) and Dunnett
and Gent (1996). The testing procedure yields one of the fol-
lowing possible conclusions:
(a) There is no signiﬁcant evidence that the new treat-
ment is either superior or equivalent to the standard
treatment.
(b) The new treatment has eﬃcacy which is equivalent to
that of the standard treatment (the diﬀerence in eﬃcacy
is small enough to be considered as clinically insigniﬁ-
cant).
(c) The new treatment is superior to the standard
treatment.
In some medical studies, there are more than one available
standard treatment. An example is the GUSTO (1993) clinical
trial to which Dunnett and Tamhane (1997) referred. A new
treatment was compared to two standard treatments (strep-
tokinase with intravenous heparin and streptokinase with sub-
cutaneous heparin) for acute myocardial infarction. Another
example is the study to evaluate the combined eﬀect of intrale-
sional corticosteroid injection with cryotherapy versus intrale-
sional corticosteroid or cryotherapy alone in the treatment of
keloids (Yosipovitch et al., 2001).
Dunnett and Tamhane (1997) derived several step-up and
step-down procedures to test the superiority and equivalence
of a new treatment compared with k standard treatments.
According to their ﬁndings, step-up procedures have higher
power than step-down procedures when all or most hypothe-
ses are false, which matches the ﬁndings of Dunnett and
Tamhane (1992). Nevertheless, all the procedures have only
small diﬀerences in terms of power except for one of the step-
up procedures, called SU3 by Dunnett and Tamhane (1997).
The power of SU3 is superior for some speciﬁc conﬁgurations
of the parameters.
Apart from the gain in power, SU3 has another advantage.
It is more sensitive to establishing equivalence (it has a higher
probability of rejecting the equivalence hypotheses). An ex-
ample is given in Table II of Dunnett and Tamhane (1997).
The establishment of equivalence between a new treatment
and the standard treatment is important. In fact, it is gaining
tremendous attention from the drug industry because generic
drug products manufactured by ﬁrms other than the inno-
vator have become more popular (Chow and Liu, 2000). An
establishment of equivalence implies that the new treatment
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can be a potential candidate as a substitute for the standard
treatment.
Even though the step-up procedures are more powerful in
general, Dunnett and Tamhane (1997) did not provide any
analytical proof that these procedures control the familywise
error rate (FWE). Kwong (2001) modiﬁed SU3 and derived a
step-up procedure (denoted by KSU hereafter) which is more
powerful than SU3. He proved that KSU controls the FWE.
All stepwise research work on superiority/equivalence test-
ing has mainly been for balanced designs. With respect to
unbalanced settings, Dunnett and Tamhane (1997) speciﬁed
two major diﬃculties in the derivation of stepwise testing pro-
cedures. First, the ordering of the test statistics for superior-
ity may be diﬀerent from the ordering of the test statistics
for equivalence; hence, the coherence requirement for multi-
ple testing is not satisﬁed. Second, the correlation structure of
the test statistics is more complex (no longer equi-correlated
but product-correlated).
For various reasons, in much medical, biological, and phys-
iological research, disparities of sample sizes are often en-
countered. Ittel et al. (1992) provided an example where few
animals died during a balanced-design experiment and the ﬁ-
nal data set became unbalanced. In this article, we derive a
method to handle multiple superiority/equivalence testing in
the unbalanced situations. In Section 2, we introduce some of
the previous work on step-up procedures. Section 3 presents
our new procedure with the unbalanced layout. In Section 4,
we discuss how to determine the critical values for the new
procedure such that the FWE is controlled at a designated
level. We conduct a simulation study in Section 5 to compare
the powers of the new procedure with the single-step proce-
dure. In Section 6, we provide a clinical example to illustrate
the application of the proposed procedure. Finally, a conclu-
sion is given in Section 7.
2. Step-Up Testing Procedures
2.1 Preliminaries
In a clinical study that is comparing a new treatment with k
standard treatments, let µi and ni be the unknown mean ef-
ﬁcacy and the sample size, respectively, for the ith treatment
(i = 0, 1, . . . , k), where 0 denotes the new treatment. The re-
sponse variable Xij that corresponds to the jth experimental
unit that is receiving the ith treatment (i = 0, . . . ,ni ) has
a normal distribution with mean µi and variance σ
2 under
the normality and homogenous error variance assumptions.
Hence, mutually independent sample means X¯i have distri-
butions N(µi, σ
2/ni ) for i = 0, . . . , k. In addition, let S2 be
an unbiased estimator of σ2, independent of all sample means,
and νS2/σ2 has a χ2 distribution with ν degrees of freedom.
Denote by θi = µ0 − µi (i = 1, . . . , k) the eﬃcacy diﬀerence
between the new treatment and the ith standard treatment.
Assume that a larger value of θi means that the new treatment
has a better eﬃcacy. The objective of this multiple hypothesis
testing is to determine whether there is signiﬁcant evidence
that the new treatment is superior or equivalent to each of
the k standard treatments.
For i = 1, . . . , k, the families of hypotheses for establishing
superiority and equivalence are
Hi : θi ≤ 0 versus θi > 0
and
H′i : θi ≤ −δ versus θi > −δ,
respectively. The quantity δ > 0 is the maximum diﬀerence
in eﬃcacy that is considered to be clinically insigniﬁcant.
Then, for the hypotheses of Hi and H
′
i , the pivotal statistics
are
Ti =
X¯0 − X¯i
Sτi
,
and
T ′i = Ti + ∆i,
respectively, for i = 1, . . . , k, where τ i = (1/ni + 1/n0)
1/2
and ∆i = δ/Sτ i. Furthermore, each set of (T 1, . . . ,Tk ) and
(T ′1, . . . ,T ′k) has a joint k-variate t-distribution with ν degrees
of freedom and a k × k correlation matrix {ρ(k)ij = ρiρj} that
has the (i, j) element equal to 1 for i = j and ρiρj for i = j,
where ρi = {ni/(ni + n0)}1/2. To take account of the mul-
tiplicity eﬀect in multiple hypothesis testing by controling
FWE, the stepwise procedures are established to satisfy the
following condition:
FWE = P{reject any true Hi or H′i} ≤ α (1)
under any conﬁguration of the parameters θi .
2.2 Dunnett and Tamhane’s Step-Up Procedure (SU3)
Assume that ti and t′i are the observed test statistics of the
corresponding random variables Ti and T ′i , respectively, for
i = 1, . . . , k. Denote the observed ordered test statistics as
t(1) ≤ · · · ≤ t(k), and t′(1) ≤ · · · ≤ t′(k) with corresponding hy-
potheses H(1), . . . , H(k) and H
′
(1), . . . , H
′
(k), respectively. In bal-
anced designs, ∆1 = · · ·= ∆k = ∆ implies that the orderings
of (t1, . . . , tk ) and (t
′
1, . . . , t
′
k) are the same, i.e., t
′
(i) = t(i) + ∆
for i = 1, . . . , k. Because δ > 0 and the diﬀerence of observed
test statistics t(i) and t′(i) is a constant for i = 1, . . . , k, the
nonrejection of H′(i) implies the nonrejection of H(i). There-
fore, for each pair of hypotheses {H′(i), H(i)} with respect to
the comparison of the new treatment to the (i)th standard
treatment, there are only three possible test conclusions:
(a) Nonrejection of H′(i)—There is no evidence that the new
treatment is either superior or equivalent to the (i)th
standard treatment.
(b) Rejection of H′(i) and nonrejection of H(i)—The new
treatment has equivalent eﬃcacy as the (i)th standard
treatment.
(c) Rejection of H′(i) and H(i)—The new treatment is supe-
rior to the (i)th standard treatment.
As stated in Section 1, SU3 is one of three step-up proce-
dures that are designed to establish the superiority and equiv-
alence of a new treatment compared to k standard treatments
for balanced designs. The testing of equivalence hypotheses
and superiority hypotheses are conducted in two stages each
with a single set of critical values {d1, d2, . . . , dk} that is deter-
mined to satisfy (1) under a conjecture. The computational
details of the constants are given by Dunnett and Tamhane
(1997). The two stages of conducting SU3 are as follows:
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Stage 1: Testing of equivalence hypotheses
Procedure: Test the equivalence hypotheses H′(1), . . . , H′(k) se-
quentially, starting with H′(1). If t′(1) ≤ d1, then H′(1) is ac-
cepted and H′(2) is tested. The testing procedure contin-
ues until the ﬁrst occurrence of t′(i) > di , say i = m1 ≤ k.
Then, H′(1), . . . , H′(m1−1) are accepted while the remaining
hypotheses are rejected. If t′(i) ≤ di , for i = 1, . . . , k, then
m1 does not exist and all the hypotheses H′(1), . . . , H′(k)
are accepted.
Decision: If m1 does not exist, then conclude that the new
treatment is inferior to all standard treatments and ter-
minate the testing procedure. Otherwise, conclude that
the new treatment is inferior to those standard treat-
ments that correspond to hypotheses H′(1), . . . , H′(m1−1)
and then proceed to Stage 2.
Stage 2: Testing of superiority hypotheses
Procedure: Test the superiority hypotheses H(m1), . . . , H(k)
sequentially, starting with H(m1). If t(m1) ≤ dm1 , then
H(m1) is accepted and H(m1+1) is tested. The testing pro-
cedure continues until the ﬁrst occurrence of t(i) > di ,
say i = m1 + m2 ≤ k. Then, H(m1), . . . , H(m1+m2−1) are
accepted while the remaining hypotheses are rejected. If
t(i) ≤ di for i = m1, . . . , k, then m2 does not exist and all
the hypotheses H(m1), . . . , H(k) are accepted.
Decision: If m2 does not exist, conclude that the new treat-
ment is equivalent to the standard treatments that cor-
respond to hypotheses H(m1), . . . , H(k). If m2 exists and
is greater than 0, then conclude that the new treatment
is equivalent to the standard treatments corresponding
to hypotheses H(m1), . . . , H(m1+m2−1) and is superior to
the standard treatments that correspond to hypotheses
H(m1+m2), . . . , H(k). In case of m2 = 0, simply conclude
that the new treatment is superior to the standard treat-
ments that correspond to hypotheses H(m1), . . . , H(k).
2.3 Kwong’s Step-Up Procedure (KSU)
There is a lack of complete analytical proof that SU3 con-
trols FWE, even though simulation studies have indicated
that it does (Dunnett and Tamhane, 1997). Recently, Kwong
(2001) modiﬁed SU3 and derived a step-up procedure (KSU).
He proved analytically that KSU controls FWE at α. Further-
more, simulation studies indicated that KSU is more powerful
in general than SU3.
The major diﬀerence between SU3 and KSU is that SU3
uses only one set of critical values in both stages and KSU uses
a diﬀerent set of critical values in each of the two stages, c01 ≤
c02 . . .≤ c0k for equivalence tests in Stage 1 and cm11 ≤ cm12 ≤
· · · ≤ cm1k−m1+1 for superiority tests in Stage 2. The method to
evaluate these constants can be found in Kwong (2001).
2.4 Coherence Property of SU3 and KSU
The parameter values that are postulated by H′i: θi ≤ −δ is
a subset of the parameter values postulated by Hi: θi ≤ 0.
According to Hochberg and Tamhane (1987), H′i is said to
imply Hi , and the hierarchical relationship between these two
hypotheses requires the satisfaction of the coherence prop-
erty (Gabriel, 1969) in multiple testing. That is, if H′i is not
rejected, then Hi is also not rejected.
It is crucial to note that both SU3 and KSU are two-stage
step-up procedures designed for n1 = · · ·= nk . Because the or-
derings of (t1, . . . , tk ) and (t
′
1, . . . , t
′
k ) are the same for balanced
designs, the decision not to reject H′(i) in Stage 1 automati-
cally leads to the nonrejection of H(i) in Stage 2. However,
for unbalanced designs, this coherence property does not ex-
ist in SU3 and KSU because the orderings of (t1, . . . , tk ) and
(t′1, . . . , t′k ) may not be the same. The lack of the coherence
property poses a major obstacle to the generalization of SU3
and KSU to unbalanced designs.
3. Proposed Step-Up Testing Procedure
for Unbalanced Designs
For various reasons, such as the availability of patients and fa-
tality of subjects during experiments, sample size disparities
are often encountered in clinical studies. In clinical experi-
ments, unbalanced designs are much more popular. Therefore,
statistical methods to compare treatments for unbalanced de-
signs are extremely useful. As indicated in Section 2, the gen-
eralization of SU3 and KSU to unbalanced designs is intricate
because the coherence property may not be preserved in un-
equal sample size cases. To overcome this obscurity, we derive
a new procedure to establish superiority and equivalence tests
for unbalanced designs.
Deviating from the SU3 and KSU, the new two-stage test-
ing procedure, denoted by KCC hereafter, consists of a step-
up procedure for establishing equivalence in Stage 1 and a
single-step procedure for establishing superiority in Stage 2.
Therefore, KCC requires a set of critical values to sequentially
compare to (t′(1), . . . , t′(k)) in Stage 1, and a single critical value
that depends on the result of Stage 1 to compare to each of
(t1, . . . ,tk ) in Stage 2. Because Stage 2 does not involve the
ordering of (t1, . . . ,tk ), the ordering problem of test statistics
does not exist in KCC.
Before testing the hypotheses, KCC requires the determi-
nation of two sets of critical values: the ﬁrst set (c1, . . . , ck )
for Stage 1 and the second set (u1, . . . , uk ) for Stage 2. Note
that only one of ui will be used in Stage 2. To preserve the
coherence property in KCC, the two sets of the critical values
must at least satisfy the following conditions:
C1: c1 ≤ c2 ≤ · · · ≤ ck ,
C2: u1 ≤ u2 ≤ · · · ≤ uk ,
C3: ci ≤ ui for i = 1, . . . , k.
The ﬁrst monotonic nondecreasing condition, C1, is the usual
requirement for any step-up procedure. The C2 and C3 condi-
tions imply that the nonrejection of any equivalence hypothe-
sis in Stage 1 guarantees the nonrejection of the corresponding
superiority hypothesis in Stage 2. The derivation and evalua-
tion of these critical values will be outlined in the next section.
The procedures of KCC are as follows:
Stage 1: Testing of equivalence hypotheses
Procedure:
(a) Test the equivalence hypotheses H′(1), . . . , H′(k) sequen-
tially, starting with H′(1). If t′(1) ≤ c1, then H′(1) is ac-
cepted and H′(2) is tested.
(b) The testing procedure continues until the ﬁrst occur-
rence of t′(i) > ci , say i = m ≤ k. Then, H′(1), . . . , H′(m−1)
are accepted while the remaining hypotheses are
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rejected. If t′(i) ≤ ci , for i = 1, . . . , k, then m does
not exist and all of the hypotheses H′(1), . . . , H′(k) are
accepted.
Decision:
(a) If m does not exist, then conclude that the new treat-
ment is inferior to all standard treatments and termi-
nate the testing procedure.
(b) If m exists, conclude that the new treatment is inferior
to those standard treatments that correspond to hy-
potheses H′(1), . . . , H′(m−1) and then proceed to Stage 2.
Stage 2: Testing of superiority hypotheses
Procedure:
(a) Let {H′l1 , H′l2 , . . . , H′lk}= {H′(1), H′(2), . . . , H′(k)}, respec-
tively. For any given hypothesis H′li tested for equiva-
lence, let Hli be the corresponding hypothesis tested
for superiority, i.e., H′li and Hli share the same treat-
ment comparison for i = 1, . . . , k. Due to the coher-
ence property of KCC, we only need to test the superi-
ority hypotheses Hlm , . . . , Hlk with the corresponding
test statistics (tlm , . . . , tlk ).
(b) Compare each of (tlm , . . . , tlk ) with the critical value
um . For j = m, . . . , k, if tlj > um , then reject Hlj ;
otherwise, accept Hlj .
Decision:
(a) If none of the superiority hypotheses is rejected, then
conclude that the new treatment is equivalent to the
standard treatments that correspond to hypotheses
Hlm , . . . , Hlk .
(b) If some superiority hypotheses are rejected and the
others are accepted, then conclude that the new treat-
ment is equivalent to the standard treatments that
correspond to the accepted hypotheses and is supe-
rior to the standard treatments that correspond to
the rejected hypotheses.
(c) If all hypotheses are rejected, then simply con-
clude that the new treatment is superior to the
standard treatments corresponding to hypotheses
Hlm , . . . , Hlk .
4. Determination of Critical Values for KCC
4.1 FWE Requirement
Let θ = (θ1, . . . , θk) and θr,s ⊂ θ be a set of vectors that have
elements θj ≤ −δ (H′j is true) for j = 1, . . . , r, θj ≤ 0 (Hj is
true) for j = r + 1, . . . , r + s, and θj > 0 (H
′
j and Hj are
false) for j = r + s + 1, . . . , k. To control the FWE at α, we
must determine the critical values of the step-up procedure in
Stage 1 of KCC such that
Pθr,0
[
Accept H′(1), . . . ,H
′
(r)
]
≥ 1− α, (2)
for r = 1, . . . , k, and the critical values of single-step procedure
in Stage 2 of KCC such that
Pθk−s,s
[
Accept H′(1), . . . ,H
′
(k−s),H1, . . . ,Hk
]
≥ 1− α, (3)
for s = 1, . . . , k, where the associated test statistics under the
null hypotheses in (2) and (3) have the parameter spaces θr,0
and θk−s,s, respectively. Note that there are k inequalities in
(2) and (3), and each inequality is supposed to derive one
critical value for KCC.
4.2 Identiﬁcation of the Least Favorable Conﬁgurations
of Parameters
Let the left-hand side of Inequality (2) be Q. For any given r,
Q is inﬂuenced by
(a) the values of parameters in θr,0, and
(b) the correlation structures among the test statistics that
correspond to those accepted true null hypotheses (Liu,
1997).
To obtain the smallest possible critical values cj for Stage 1
of KCC, we have to determine minimum value of Q over all
possible conﬁgurations in (a) and (b). Based on the arguments
given by Liu (1997) for establishing a step-up procedure for
unbalanced designs, the minimum value of Q is
min∗ Pθ∗
r,0
[
Accept H′(1), . . . ,H
′
(r)
]
, (4)
where min∗ denotes the minimum over all possible correlation
structures among the test statistics corresponding to those
accepted true null hypotheses, and θ∗r,s ∈ θr,s denotes a pa-
rameter vector with elements θj = −δ for j = 1, . . . , r, θj =
0 for j = r + 1, . . . , r + s, and θj → ∞ for j = r + s +
1, . . . , k. In other words, the operator min∗ minimizes Q over
all the possible product correlation structures among the test
statistics under θ∗r,0. By setting (4) to 1 − α, the minimum
possible critical values c1 ≤ c2 ≤ · · · ≤ ck used in Stage 1 can
be determined.
Similarly, the minimum value of the left hand of Inequality
(3) is
min∗ Pθ∗
k−s,s
[
Accept H′(1), . . . ,H
′
(k−s),H1, . . . ,Hk
]
(5)
and the minimum possible critical values u1 ≤ u2, ≤ · · · ≤ uk
used in Stage 2 can be evaluated by equating (5) to 1 − α.
4.3 Critical Values in Stage 1
Denote (a1, . . . , ak ) ≤ (b1, . . . , bk ) in the event that a(j) ≤ b(j)
for j = 1, . . . , k, where a(1) ≤ · · · ≤ a(k) and b(1) ≤ · · · ≤ b(k) are
the ordered values of aj ’s and bj ’s, respectively. Following the
arguments of (4), assume that H′(1), . . . , H′(r) are true and all
other hypotheses are false, in order to determine the critical
values of Stage 1, cr for r = 1, . . . , k. Therefore, by setting
the probability in (4) to 1 − α, we obtain the following k
equations
min
1≤l1<···<lr≤k
Pθ∗
r,0
[(
T ′l1 , . . . , T
′
lr
)
< (c1, . . . , cr);{
ρ
(r)
ij = ρliρlj
}]
= 1− α, (6)
for r = 1, . . . , k. The minimum is taken over all the subsets
{l1, . . . , lr} ⊂ {1, . . . , k} with cardinality r. The set of random
variables (T ′l1 , . . . ,T
′
lr ) for r = 2, . . . , k has standardized mul-
tivariate t-distribution with correlation matrix {ρ(r)ij = ρliρlj}.
For r = 1, (6) produces c1, which is the upper α-percentage
point of the t-distribution with ν degrees of freedom. After-
wards, we can solve recursively for cr (r = 2, . . . , k) based on
the previously determined values c1, . . . , cr−1.
From the above arguments, it is trivial that c1, . . . , ck do not
depend on δ and are equivalent to the critical values of the
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conventional one-sided step-up procedure that was discussed
by Dunnett and Tamhane (1995), Liu (1997), and Kwong and
Liu (2000) for unbalanced designs. Therefore, one can adopt
the techniques that were discussed by Kwong and Liu (2000)
to eﬃciently evaluate the exact or approximate critical values
that are used in Stage 1 of KCC.
4.4 Critical Values in Stage 2
To determine the critical values u1, . . . ,uk for Stage 2 of KCC,
we follow arguments that are similar to those given in Sec-
tion 4.3. Assume that H′(1), . . . , H′(s−1), H1, . . . , Hk are true. By
setting the probability in (5) to 1 − α, we solve the following
k equations for the critical values us :
min∗Pθ∗
s−1,k−s+1
[
Accept H′(1), . . . ,H
′
(s−1),H1, . . . ,Hk
]
= 1− α,
(7)
for s = 1, . . . , k. The critical values are determined recursively,
starting from uk . Then, use uk to determine uk−1 until u1 is
obtained.
Consider the general case to evaluate us based on the pre-
viously determined values c1, . . . , ck and us+1, . . . ,uk . Deﬁne
the subsets S = {l1, . . . , ls−1} ⊂ {1, . . . , k} with cardinality
s − 1. Note that there are q1 = ( ks− 1) distinct subsets, say
S1, . . . ,Sq1 in S. For each given subset Sj for j = 1, . . . , q1,
let the complement of Sj be Scj = {ls , . . . , lk}. Deﬁne the sub-
sets I(j, h) = {lg1 , . . . , lgh) ⊂ Scj with cardinality h and the
complement of I(j, h) be {lgh+1, . . . , lgk−s+1}. Note that there
are q2 = (
k − s+ 1
h ) distinct subsets of I(j, h), say I1, . . . , Iq2 .
Due to the coherence property of KCC stated in Section 3,
the nonrejection of any equivalence hypothesis implies the
nonrejection of corresponding superiority hypothesis. As a re-
sult, (5) is equivalent to
min∗Pθ∗
s−1,k−s+1
[
Accept H′(1), . . . ,H
′
(s−1),H1, . . . ,Hk
]
= min∗
{
Pθ∗
s−1,k−s+1
[
Accept H′(1), . . . ,H
′
(k)
]
+
k−s∑
h=0
Pθ∗
s−1,k−s+1
[
Accept H′(1), . . . ,H
′
(s−1+h),
H1, . . . ,Hk and Reject H
′
(s+h)
]}
= min
Sj∈S


k−s+1∑
h=0
∑
Ip∈I(j,h)
Pθ∗
s−1,k−s+1
[(
T ′l1 , . . . , T
′
ls−1 , T
′
lg1
, . . . , T ′lgh
)
≤ (c1, . . . , cs−1+h),
k−s+1⋂
i=h+1
cs+h −∆lgi < Tlgi
≤ us+h;
{
ρ
(k)
ij = ρliρlj
}]}
= min
Sj∈S


k−s+1∑
h=0
∑
Ip∈I(j,h)
Pθ∗
s−1,k−s+1
[(
T ′l1 , . . . , T
′
ls−1 , T
′
lg1
, . . . , T ′lgh
)
≤ (c1, . . . , cs−1+h),
k−s+1⋂
i=h+1
cs+h < T
′
lgi
≤ us+h + ∆lgi ;
{
ρ
(k)
ij = ρliρlj
}]}
, (8)
for j = 1, . . . , q1 and p = 1, . . . , q2, where (T
′
l1 , . . . ,T
′
ls−1) and
(T ′lg1 , . . . ,T
′
lgk−s+1 ) have parameters θi equal to (−δ, . . . ,−δ)
and (0, . . . , 0), respectively.
By applying arguments that are similar to those given by
Dunnett and Tamhane (1995), we transform (T ′l1 , . . . ,T
′
ls−1 ,
T ′lg1 , . . . ,T
′
lgk−s+1 ) to
T ′li =
√
1− ρ2liZli − ρliZ0
U
for i = 1, . . . , s− 1.
T ′lgi =
√
1− ρ2lgiZlgi − ρlgiZ0
U
+ ∆lgi
for i = 1, . . . , k − s+ 1,
where Z0, Zl1 . . . ,Zls−1 , Zlg1 , . . . ,Zlgk−s+1 are mutually inde-
pendent standard normal random variables with probability
density function φ, and U, which is independent of all Zi , is
the random variable (χ2ν/ν)
1/2 with probability density func-
tion fν . After conditioning on the two random variables U =
u and Z0 = z0, and interchanging the order of summation and
integration, (8) is reduced to
min∗Pθ∗
s−1,k−s+1
{
Accept H′(1), . . . ,H
′
(s−1),H1, . . . ,Hk
}
= min
Sj∈S
∫ ∞
0
∫ ∞
−∞

k−s+1∑
h=0
∑
Ip∈I(j,h)
P
[(
Wl1 , . . . ,Wls−1 ,Wlg1 , . . . ,Wlgh
)
≤ (c1, . . . , cs−1+h)
]
×
k−s+1∏
i=h+1
P
[
cs+h < Wlgi ≤ us+h + ∆lgi
]}
×φ(z0) dz0fν(u) du, (9)
for j = 1, . . . , q1 and p = 1, . . . , q2, where (W l1 , . . . ,W ls−1 ,
W lg1 , . . . ,W lgk−s+1 ) are mutually independent random vari-
ables with distributions:
Wli ∼ N
(−ρliz0
u
,
1− ρ2li
u2
)
for i = 1, . . . , s− 1.
Wlgi∼ N
(−ρlgi z0
u
+ ∆lgi ,
1− ρ2lgi
u2
)
for i = 1, . . . , k − s+ 1.
Based on (9), the critical values us (s = 1, . . . , k) are deter-
mined for Stage 2 of KCC, and we show that KCC controls
the FWE at α for unbalanced designs.
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Table 1
Critical values of KCC for α = 0.05
Standard treatments
New
treatment i
δ i = 0 1 2 3 4 5 6
ni 20 10 15 20
ci 1.670 1.982 2.129
ui 0.5 1.673 2.030 2.174
1.0 1.762 2.117 2.242
1.5 1.839 2.228 2.336
2.0 1.912 2.363 2.460
ni 30 10 21 23 25
ci 1.660 1.971 2.120 2.220
ui 0.5 1.660 2.027 2.159 2.250
1.0 1.674 2.111 2.220 2.297
1.5 1.819 2.209 2.299 2.365
2.0 1.914 2.324 2.401 2.457
ni 20 10 12 21 25 30
ci 1.659 1.967 2.111 2.205 2.271
ui 0.5 1.659 1.967 2.152 2.240 2.308
1.0 1.848 2.060 2.242 2.312 2.371
1.5 1.942 2.230 2.352 2.412 2.465
2.0 2.034 2.384 2.488 2.543 2.594
ni 24 10 12 15 18 23 30
ci 1.657 1.967 2.119 2.220 2.294 2.348
ui 0.5 1.657 1.967 2.119 2.220 2.311 2.372
1.0 1.849 2.073 2.208 2.277 2.356 2.415
1.5 1.942 2.215 2.296 2.358 2.422 2.483
2.0 2.030 2.336 2.401 2.457 2.513 2.581
δ is in the scale of s/
√
n0.
4.5 Numerical Study
Applying the approach discussed by Kwong and Liu (2000),
a FORTRAN program to evaluate all the critical values of
KCC for any given α, n0, n1, . . . ,nk and δ is available from
the ﬁrst author. From various extensive numerical studies, we
ﬁnd that it is always possible to evaluate the critical values
that satisfy conditions C1 and C2 for any given conﬁgurations
of parameters. Occasionally, for small δ and/or large dispar-
ity among ni , there may be cases where ui < ci . To satisfy
Table 2
Simulated average powers for the case α = 0.05, (n0, . . . , n6) = (24, 10, 12, 15, 18, 23, 30), s/
√
n0 = 1, δ = 1
θ P1 P2
θ1 θ2 θ3 θ4 θ5 θ6 KCC SS KCC SS
−1 −1 −1 −1 −1 2 0.456 0.456 0.190 0.196
−1 −1 −1 −1 −1 4 0.915 0.915 0.724 0.736
−1 −1 −1 2 2 2 0.426 0.403 0.183 0.173
−1 −1 −1 4 4 4 0.889 0.870 0.695 0.673
−1 2 2 2 2 2 0.415 0.358 0.190 0.154
−1 4 4 4 4 4 0.878 0.818 0.690 0.611
2 2 2 2 2 2 0.426 0.338 0.206 0.146
4 4 4 4 4 4 0.892 0.789 0.719 0.581
P1 is deﬁned as the proportion of rejecting equivalence hypotheses H′j , given that θj > −δ.
P2 is deﬁned as the proportion of rejecting superiority hypotheses Hj , given that θj > 0.
condition C3, the value of ui is adjusted slightly upward to
ci . Numerical examples of critical values used in KCC are
presented in Table 1, where δ is in the scale of s/(n0)
1/2.
5. Simulation Study of Power
Currently, the only proved statistical method to establish the
superiority and equivalence of a new treatment compared to k
standard treatments for unbalanced designs is the single-step
procedure (SS) proposed by Dunnett and Tamhane (1997).
Hence, we conducted a simulation study to compare the pow-
ers of KCC to SS for the case where α = 0.05, (n0, . . . ,n6) =
(24, 10, 12, 15, 18, 23, 30), s/(n0)
1/2 = 1, δ = 1. We observed
similar results for some other cases, but they are not reported
here. The number of repetitions in each conﬁguration of θ is
1,000,000, so that the standard error of each simulated power
is less than 0.0005. The critical values for KCC are stated in
Table 1 and the critical value for SS is 2.347 in this case. The
simulated powers of KCC and SS are presented in Table 2,
where the average power P1 is deﬁned as the proportion of
rejecting equivalence hypotheses H′j , given that θj > −δ, and
the average power P2 is deﬁned as the proportion of rejecting
superiority hypotheses Hj , given that θj > 0. Table 2 reveals
that KCC is more powerful in terms of P1 and P2 than SS in
general. Furthermore, when most of the equivalence or supe-
riority hypotheses are false, the superiority of the KCC proce-
dure is drastic, where the gain in power is well above 10% in
most of the conﬁgurations. Therefore, we conclude that KCC
not only controls the FWE, but is also more powerful than its
counterpart SS in unequal sample size cases, especially when
most of the equivalence or superiority hypotheses are false.
6. Example
Malmstrom et al. (2002) recently conducted a single-center,
randomized, double-blind, single-dose study of certain anal-
gesic drugs that treated pain after dental surgery. The objec-
tive of the study was to reconﬁrm the analgesic eﬃcacy of a
relatively new treatment, rofecoxib 50 mg (r50) by comparing
it to four standard treatments: celecoxib 400 mg (c400), cele-
coxib 200 mg (c200), ibuprofen 400 mg (ib400), and placebo
(plac). After the surgical extraction of at least 2 third molars,
patients with moderate or severe pain were randomly given
a single oral dose of one of the ﬁve treatments. A 0–4 scale
for pain relief (0 = poor, 1 = fair, 2 = good, 3 = very good,
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Table 3
Critical values of KCC with δ = 0.815 and α = 0.05 for
testing the superiority/equivalence of the dental data
Standard treatments
New i
treatment
i = 0 1 2 3 4
ni 150 45 151 90 45
ci 1.648 1.958 2.110 2.208
ui 1.718 1.958 2.166 2.284
and 4 = excellent) recorded the pain intensity that was ex-
perienced by patients throughout the 24 hours after dosing.
The primary end point was the total pain relief score over the
ﬁrst 8 hours.
After applying the well-known Bartlett’s test, we have no
reason to doubt the equality of variances among the ﬁve treat-
ments. The estimate of the common variance is s2 = 99.584.
Because the clinically insigniﬁcant diﬀerence δ is not given in
the study and KCC and SS are only appropriate for a pre-
speciﬁed value of δ, we set δ to be 1 s/(n0)
1/2, or 0.815 for
illustrative purposes. We also set the overall signiﬁcance level
at 0.05. Table 3 provides the critical values that are necessary
to implement the KCC procedure. For the SS procedure, the
critical value is 2.205. Table 4 summarizes the conclusions.
With the KCC procedure, the new treatment r50 is superior
to c400, c200, and plac, and equivalent to ib400. If the SS pro-
cedure is used, then the new treatment is found to be superior
to c200 and plac, and equivalent to c400 only. The ﬁndings
demonstrate that the KCC procedure is more powerful than
the SS procedure.
7. Conclusion
We have proposed a two-stage testing procedure to establish
superiority/equivalence of a new treatment compared with k
standard treatments for unbalanced designs. The new pro-
cedure is a combination of the step-up method for testing
equivalence and the single-step method for testing superior-
ity. A theoretical justiﬁcation is provided to show that the new
procedure controls the familywise error rate at a designated
level.
Existing stepwise procedures to establish superiority/
equivalence are more powerful than the single-step procedure,
Table 4
Dental data for establishing superiority/equivalence with δ =
0.815 and α = 0.05 under the KCC and SS procedures
i Contrast t′(i) ti
1 r50 vs. ib400 1.954a 1.474
2 r50 vs. c400 2.620a,c 1.912b
3 r50 vs. c200 4.896a,c 4.284b,d
4 r50 vs. plac 10.218a,c 9.728b,d
aSigniﬁcance for the equivalence tests under KCC.
bSigniﬁcance for the superiority tests under KCC.
cSigniﬁcance for the equivalence tests under SS.
dSigniﬁcance for the superiority tests under SS.
but they are restricted to balanced designs. The major con-
tribution of this article is to extend the stepwise procedures
of Dunnett and Tamhane (1997) to unbalanced designs. Our
proposed method should be useful in many practical circum-
stances. In addition, with the help of the algorithm stated in
this article, practitioners will ﬁnd the evaluation of the criti-
cal values for the new procedure straightforward and feasible.
Furthermore, our simulation study reveals that the new pro-
cedure is also more powerful than the single-step procedure in
general, especially when most of the hypotheses are false.
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Re´sume´
Dans les e´tudes cliniques, des proce´dures de tests multi-
ples de supe´riorite´/e´quivalence peuvent eˆtre utilise´es pour
classer un nouveau traitement en supe´rieur, e´quivalent(meˆme
eﬀet the´rapeutique) ou infe´rieur a` chacun des traitements
de re´fe´rence.De pre´ce´dentes approches pas-a`-pas (Dunnett
et Tamhane,1997, Statistics in Medicine 16, 2489–506;
Kwong, 2001, Journal of Statistical Planning and Inference
97, 359–366) sont approprie´es seulement pour des sche´mas
e´quilibre´s. Malheureusement, la construction de tests sim-
ilaires pour des sche´mas de´se´quilibre´s est bien plus com-
plexe, avec deux diﬃculte´s majeures: (i) l’ordre des statis-
tiques de test pour la supe´riorite´ peut ne pas eˆtre la
meˆme que l’ordre des statistiques de test pour l’e´quivalence;
et (ii) la structure de corre´lation des statistiques de test
n’est plus e´quicorre´le´e.Dans ce papier,nous cherchons a`
de´velopper une proce´dure de test a` deux e´tapes pour sche´mas
de´se´quilibre´s,proce´dures tre`s populaires dans le domaine des
essais cliniques. Cette proce´dure est la combinaison d’une
proce´dure ascendante pas-a`-pas et d’une proce´dure a` une
e´tape,tandis qu’il est prouve´ que le taux d’erreur globale est
controˆle´ au niveau voulu.En outre,une e´tude de simulation
est conduite aﬁn de comparer la puissance moyenne de cette
proce´dure avec celle de la proce´dure a` une e´tape.Enﬁn,un ex-
emple clinique est fourni pour illuster l’application de cette
nouvelle proce´dure.
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